Sequana Medical NV announces that all proposed resolutions submitted to the extraordinary general meeting of shareholders were approved at the meeting held February 10, 2023 at 09:00 am CET.
REGULATED INFORMATION
Ghent, Belgium – 10 February 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “SequanaMedical”), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that all proposed resolutions submitted to the extraordinary general meeting of shareholders were approved at the meeting held today at 09:00 am CET.
The items on the agenda of the meeting included (amongst other things) the approval of the appointment of Douglas Kohrs and Alexandra Taylor Clyde as independent non-executive directors, the approval of certain amendments to the Company’s remuneration policy, and the issuance of “Kreos Subscription Rights” (in the form of subscription rights).
The minutes of the shareholders’ meeting can be accessed on the Company’s website.
For more information, please contact:
Sequana Medical
Lies Vanneste
Director Investor Relations
E: IR@sequanamedical.com
T: +32 (0)498 05 35 79
Optimum Strategic Communications
Nick Bastin, Jonathan Edwards, Vici Rabbetts
E: Sequana@optimumcomms.com
T: +44 (0) 208 078 4357
About Sequana Medical
Sequana Medical NV is a pioneer in treating fluid overload, a serious and frequent clinical complication in patients with liver disease, heart failure and cancer. These patients can have up to 15 liters of extra fluid in their bodies, causing major medical issues including increased mortality, repeated hospitalizations, severe pain, difficult breathing and restricted mobility that severely impacts daily life. Although diuretics are standard of care, the problem is that in many patients they are no longer effective and / or tolerable. There are limited effective treatment options for these patients resulting in poor clinical outcomes, high costs and major impact on their quality of life. Sequana Medical is seeking to provide innovative treatment options for this large and growing “diuretic-resistant” patient population.
alfapump® and DSR® are Sequana Medical’s proprietary platforms that work with the body to treat diuretic-resistant fluid overload, delivering major clinical and quality of life benefits for patients and reducing costs for healthcare systems. The Company has reported positive primary endpoint data from the North American pivotal POSEIDON study of the alfapump in recurrent or refractory ascites due to liver cirrhosis, enabling the filing of a Pre-Market Approval (PMA) application with the FDA, planned for H2 2023. Having delivered clinical proof-of-concept for DSR as a disease-modifying drug program for the treatment of heart failure, the Company is planning to commence MOJAVE, a US multi-centered randomized controlled Phase 1/2a clinical study of DSR 2.0, in Q2 2023.
Sequana Medical is listed on Euronext Brussels (Ticker: SEQUA.BR) and headquartered in Ghent, Belgium. For further information, please visit www.sequanamedical.com.
Important Regulatory Disclaimers
The alfapump® system is currently not approved in the United States or Canada. In the United States andCanada, the alfapump system is currently under clinical investigation (POSEIDON Study) and is being studied inadult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding thePOSEIDON clinical study see www.poseidonstudy.com. DSR® therapy is still in development and it should benoted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinicalinvestigations which have yet to be completed. DSR therapy is currently not approved for clinical research in theUnited States or Canada. There is no link between DSR therapy and ongoing investigations with the alfapumpsystem in Europe, the United States or Canada.
Note: alfapump® is a registered trademark. DSR® is a registered trademark in the Benelux, China, the EU, UnitedKingdom, and Hong Kong.
Forward-looking statements
This press release may contain predictions, estimates or other information that might be consideredforward-looking statements. Such forward-looking statements are not guarantees of future performance.Theseforward-looking statements represent the current judgment of Sequana Medical on what the futureholds,and are subject to risks and uncertainties that could cause actual results to differ materially. Sequana Medicalexpressly disclaims any obligation or undertaking to release any updates or revisions to any forward-lookingstatements in this press release, except if specifically required to do so by law or regulation. You should notplace undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as ofthe date of this press release.
Attachments
